12 hours ago
Innovent Biologics announces first participant dosed in Phase 3 GLORY-OSA
Innovent Biologics (IVBXF) announced that the first participant has been successfully dosed in a Phase 3 clinical trial, GLORY-OSA, of mazdutide, a dual glucagon and glucagon-like peptide-1 receptor agonist, in Chinese participants with moderate-to-severe obstructive sleep apnea and obesity. This is the seventh Phase 3 clinical study of mazdutide in China, continuing to explore its potential in managing obesity and a range of metabolic syndromes, with the aim of generating more comprehensive and high-quality evidence to support clinical application.
Confident Investing Starts Here:
